[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350473-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350473-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gamabufotalin-suppresses-pancreatic-cancer-through-redox-homeostasis-disruption-by-g6pd-downregulation","Gamabufotalin suppresses pancreatic cancer through redox-homeostasis disruption by G6PD downregulation","","Pancreatic cancer remains a leading cause of cancer-related mortality, driving demand for new therapeutic approaches. This study evaluates Gamabufotalin (CS-6), a bufadienolide compound, as a candidate treatment for pancreatic cancer and clarifies its molecular basis. In vitro and in vivo experiments show CS-6 suppresses tumor growth and promotes apoptosis, with G6PD downregulation disrupting redox homeostasis, elevating ROS, and triggering autophagy-related cell death. Mechanistic work implicates PI3K/AKT pathway inhibition.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gamabufotalin-suppresses-pancreatic-cancer-through-redox-homeostasis-disruption-by-g6pd-downregulation/350473/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gamabufotalin-suppresses-pancreatic-cancer-through-redox-homeostasis-disruption-by-g6pd-downregulation/350473.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study on Gamabufotalin (CS-6)?","Question",{"text":63,"@type":64},"To assess the therapeutic potential of CS-6 against pancreatic cancer and determine the underlying molecular mechanisms, focusing on G6PD and redox homeostasis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CS-6 affect pancreatic cancer cells and tumor growth?",{"text":68,"@type":64},"CS-6 inhibits pancreatic cancer cell growth, migration, and invasion, promotes apoptosis, and in vivo suppresses tumor growth while inducing cell death.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is G6PD important in the proposed mechanism of CS-6?",{"text":72,"@type":64},"CS-6 treatment reduces NADPH levels and increases ROS accumulation alongside decreased G6PD protein expression, indicating that G6PD downregulation drives redox-homeostasis disruption and downstream effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350473,1790151205,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Xu etal. Journal of Translational Medicine (2026) 24:795  \n[https://doi.org/10.1186/s12967-026-08441-2](https://doi.org/10.1186/s12967-026-08441-2)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nGamabufotalin suppresses pancreatic cancer  through redox-homeostasis disruption  \nby G6PD downregulation  \nDie Xu1, Xiaowei Wang2, Yisi Cai1, Piao Zheng3,4, Lemei Zhu4, Weijun Peng1*, Yinghui Song5* and Bolin Chen6*  \nAbstract  \nBackground Pancreatic cancer is a leading cause of cancer-related deaths worldwide, highlighting the critical need for novel therapeutic strategies. Gamabufotalin (CS-6), a bufadienolide compound, has been shown to exert significant inhibitory effects on a variety of cancers.  \nObjective This study investigates the potential therapeutic effects and underlying molecular mechanisms of CS-6 in pancreatic cancer.  \nMethods The anti-cancer properties of CS-6 were assessed through both in vivo and in vitro experiments. Network pharmacology and untargeted metabolomics were employed to identify candidate molecular targets of CS-6 . Molecular docking, molecular dynamics simulations, and CETSA were used to support potential target engagement between CS-6 and G6PD. G6PD expression was evaluated through public databases and immunohistochemistry. NADPH levels, ROS accumulation, apoptosis, and autophagy were measured using NADPH assays, western blot, flow cytometry, and transmission electron microscopy. Transcriptomic analysis and western blot were conducted to explore the downstream signaling pathways affected by G6PD downregulation.  \nResults CS-6 inhibited pancreatic cancer cell growth, migration, and invasion, while promoting apoptosis. In  \nvivo, CS-6 suppressed tumor growth and induced cell death. Elevated G6PD expression in pancreatic cancer was associated with poor prognosis. CS-6 treatment reduced NADPH levels, increased ROS accumulation, and was associated with autophagy induction, accompanied by decreased G6PD protein expression. Furthermore, CS-6 inhibited the PI3K/AKT signaling pathway, and G6PD knockdown recapitulated this effect.  \nConclusion CS-6 treatment is associated with G6PD downregulation, redox-homeostasis disruption, and suppression of the PI3K/AKT signaling pathway, thereby contributing to autophagy-related cell death, apoptosis, and inhibition of pancreatic cancer progression. These findings highlight CS-6 as a promising therapeutic candidate for pancreatic cancer treatment, with G6PD as a potential molecular target.  \n*Correspondence:  \nWeijun Peng [pengweijun87@csu.edu.cn](pengweijun87@csu.edu.cn)[ ](pengweijun87@csu.edu.cn)Yinghui Song [songyinghui@hunnu.edu.cn](songyinghui@hunnu.edu.cn)[ ](songyinghui@hunnu.edu.cn)Bolin Chen[chenbolin@hnca.org.cn](chenbolin@hnca.org.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nXu et al. Jou","cbCailLlseJeubiy","https://ap.wps.com/l/cbCailLlseJeubiy","pdf",22141782,"English","# Abstract\n## Background and Objective\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Clinical challenges in pancreatic cancer\n## Cell death, apoptosis, and autophagy\n## Role of Traditional Chinese Medicine and Gamabufotalin","[{\"question\":\"What is the main purpose of the study on Gamabufotalin (CS-6)?\",\"answer\":\"To assess the therapeutic potential of CS-6 against pancreatic cancer and determine the underlying molecular mechanisms, focusing on G6PD and redox homeostasis.\"},{\"question\":\"How does CS-6 affect pancreatic cancer cells and tumor growth?\",\"answer\":\"CS-6 inhibits pancreatic cancer cell growth, migration, and invasion, promotes apoptosis, and in vivo suppresses tumor growth while inducing cell death.\"},{\"question\":\"Why is G6PD important in the proposed mechanism of CS-6?\",\"answer\":\"CS-6 treatment reduces NADPH levels and increases ROS accumulation alongside decreased G6PD protein expression, indicating that G6PD downregulation drives redox-homeostasis disruption and downstream effects.\"}]","Gamabufotalin suppresses pancreatic cancer through redox-homeostasis disruption by G6PD downregulation | PDF",1790089229,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/958bdf1103b3ccaa3ba8899b9ab6f904.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c5ecb5da47f2069c9b634bb8fe5cdff.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7371fcf834d92f9e2000924a2a06fc0b.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58469184d276d14d68ae3606a98a5d64.webp",980,1306]